Epidemiology, risk factors and outcome of Candida parapsilosis bloodstream infection in children

Pediatric Infectious Disease Journal

Volumn 31, Issue 6, 2012, Pages 557-560

  Dotis, John ^a   Prasad, Priya A ^b   Zaoutis, Theoklis ^b   Roilides, Emmanuel ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Candida parapsilosis; Candidemia; Children; Risk factors

Indexed keywords

ECHINOCANDIN; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; POLYENE ANTIBIOTIC AGENT;

ARTICLE; ARTIFICIAL VENTILATION; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDEMIA; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; HOSPITAL INFECTION; HUMAN; INFECTION RISK; INTRAVASCULAR CATHETER; MAJOR CLINICAL STUDY; MORTALITY; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; URINARY CATHETER;

ADOLESCENT; AGE FACTORS; CANDIDA; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROSS INFECTION; FEMALE; HOSPITALS, PEDIATRIC; HUMANS; INFANT; MALE; PHILADELPHIA; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84861530224     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31824da7fe     Document Type: Article

References (25)

1. Chang A, Neofytos D, Horn D. Candidemia in the 21st century. Future Microbiol. 2008;3:463-472.
2. Roilides E, Farmaki E, Evdoridou J, et al. Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis. 2004;23:745-750.
3. Celebi S, Hacimustafaoglu M, Ozdemir O, et al. Nosocomial candidaemia in children: results of a 9-year study. Mycoses. 2008;51:248-257.
4. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133-163.
5. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: Data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695-1703.
6. Conde-Rosa A, Amador R, Pérez-Torres D, et al. Candidemia distribution, associated risk factors, and attributed mortality at a university-based medical center. P R Health Sci J. 2010;29:26-29.
7. Zaoutis T. Candidemia in children. Curr Med Res Opin. 2010;26:1761-1768.
8. Levy I, Rubin LG, Vasishtha S, et al. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis. 1998;26:1086-1088.
9. da Silva CL, dos Santos RM, Colombo AL. Cluster of Candida parapsilosis primary bloodstream infection in a neonatal intensive care unit. Braz J Infect Dis. 2001;5:32-36.
10. Clark TA, Slavinski SA, Morgan J, et al. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol. 2004;42:4468-4472.
11. Neu N, Malik M, Lunding A, et al. Epidemiology of candidemia at a Children's hospital, 2002 to 2006. Pediatr Infect Dis J. 2009;28:806-809.
12. Kuhn DM, Chandra J, Mukherjee PK, et al. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun. 2002;70:878-888.
13. Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev. 2008;21:606-625.
14. van Asbeck EC, Clemons KV, Stevens DA. Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit Rev Microbiol. 2009;35:283-309.
15. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128-140.
16. Tortorano AM, Peman J, Bernhardt H, et al.; ECMM Working Group on Candidaemia. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis. 2004;23:317-322.
17. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol. 2006;44:1782-1787.
18. Pfaller MA, Diekema DJ, Gibbs DL, et al.; Global Antifungal Surveillance Study. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2007;45:1735-1745.
19. Blyth CC, Chen SC, Slavin MA, et al.; Australian Candidemia Study. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics. 2009;123:1360-1368.
20. Almirante B, Rodríguez D, Cuenca-Estrella M, et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. 2006;44:1681-1685.
21. Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics. 2006;117:1680-1687.
22. Zaoutis TE, Greves HM, Lautenbach E, et al. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J. 2004;23:635-641.
23. Pappas PG, Rex JH, Lee J, et al.; NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37:634-643.
24. Kuhn DM, Mikherjee PK, Clark TA, et al. Candida parapsilosis characterization in an outbreak setting. Emerging Infect Dis. 2004;10:1074-1081.
25. Arendrup M, Horn T, Frimodt-Møller N. In vivo pathogenicity of eight medically relevant Candida species in an animal model. Infection. 2002;30:286-291.